News
ACRS
14.05
-1.95%
-0.28
Insider Sell: Aclaris Therapeutics
Insider Sell: Aclaris Therapeutics
MT Newswires · 22h ago
Aclaris Therapeutics Has Strong Upside Potential, But Shares Could Be Lower
Seeking Alpha · 01/10 21:04
Aclaris Therapeutics (ACRS) Receives a Buy from BTIG
TipRanks · 01/09 04:25
Aclaris Therapeutics Expects Key Data Read-Outs From Two Lead Clinical Programs in 2023
Aclaris Therapeutics Expects Key Data Read-Outs From Two Lead Clinical Programs in 2023
MT Newswires · 01/06 08:07
Stifel Nicolaus Initiates Coverage on Aclaris Therapeutics With Buy Rating, $29 Price Target
Stifel Nicolaus Initiates Coverage on Aclaris Therapeutics With Buy Rating, $29 Price Target
MT Newswires · 12/14/2022 08:14
Benzinga's Top Ratings Upgrades, Downgrades For December 1, 2022
Benzinga · 12/01/2022 15:01
Goldman Sachs Initiates Aclaris Therapeutics at Buy With $25 Price Target
Goldman Sachs Initiates Aclaris Therapeutics at Buy With $25 Price Target
MT Newswires · 12/01/2022 10:14
BRIEF-Aclaris Therapeutics & Pediatrix Therapeutics Announce License Agreement For Ati-1777 In China
Reuters · 11/29/2022 12:28
Aclaris Therapeutics And Pediatrix Therapeutics Announce License Agreement For ATI-1777 In Greater China; Aclaris To Receive $5M Upfront Payment And Up To $91M In Milestones
Benzinga · 11/29/2022 12:04
Aclaris Therapeutics Announces Key Leadership Transitions; Douglas Manion, M.D. Appointed To Succeed Dr. Walker As CEO And Appointed To The Board Of Directors; Kevin Balthaser Appointed CFO To Succeed Retiring Frank Ruffo
Benzinga · 11/22/2022 21:03
Aclaris Therapeutics Announces Key Leadership Transitions
- Dr. Neal Walker to transition to Chair of the Board of Directors - Current Board Chair Christopher Molineaux to become Lead Independent Director - Douglas Manion, M.D. appointed to succeed Dr. Walker as Chief Executive Officer and appointed to the Board ...
GlobeNewswire · 11/22/2022 21:01
Aclaris Therapeutics Names New Leadership Team With Christopher Molineaux as Chief Executive Officer
Aclaris Therapeutics Names New Leadership Team With Christopher Molineaux as Chief Executive Officer
MT Newswires · 11/22/2022 17:35
Aclaris Therapeutics Looks Promising on the Charts
Aclaris Therapeutics is a biotech play that is focused on "leveraging core expertise in drug discovery and development and kinase inhibition to develop novel, small molecule therapies to help people impacted by under served immuno-inflammatory conditions....
TheStreet.com · 11/16/2022 17:10
Aclaris Therapeutics to Participate in Two November Healthcare Investor Conferences
WAYNE, Pa., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that the company will particip...
GlobeNewswire · 11/10/2022 21:01
Aclaris Therapeutics (ACRS) Reports Q3 Loss, Tops Revenue Estimates
Aclaris (ACRS) delivered earnings and revenue surprises of 23.08% and 1,083.45%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 11/08/2022 13:25
Aclaris Therapeutics Q3 EPS $(0.30) Up From $(0.35) YoY, Sales $19.02M Up From $1.66M YoY
Benzinga · 11/08/2022 12:08
Aclaris Therapeutics Reports Narrower Q3 Loss, Higher Revenue
Aclaris Therapeutics Reports Narrower Q3 Loss, Higher Revenue
MT Newswires · 11/08/2022 09:45
-- Earnings Flash (ACRS) ACLARIS THERAPEUTICS Posts Q3 Revenue $19M
-- Earnings Flash (ACRS) ACLARIS THERAPEUTICS Posts Q3 Revenue $19M
MT Newswires · 11/08/2022 07:18
Notable earnings before Tuesday's open
Seekingalpha · 11/07/2022 16:03
More
Webull provides a variety of real-time ACRS stock news. You can receive the latest news about Aclaris Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About ACRS
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on developing drug candidates for immuno-inflammatory diseases. The Company is focused on leveraging its experience in drug discovery and development and kinase inhibition to develop small molecule therapies to help people impacted immuno-inflammatory conditions. The Company’s drug candidates are Zunsemetinib (ATI-450), ATI-1777 and ATI-2138. The Company’s ATI-450, an investigational oral, small molecule selective MK2 inhibitor compound, for the treatment of rheumatoid arthritis. Its ATI-1777, an investigational topical soft-JAK 1/3 inhibitor compound, for the treatment of atopic dermatitis. The Company is engaged in developing ATI-2138, its investigational oral inhibitor compound, as a potential treatment for T-cell mediated autoimmune diseases. It is also developing oral gut biased JAK inhibitors, as a potential treatment for inflammatory bowel disease.